心血管药物市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球心血管药物市场价值为 1,537 亿美元，预计到 2034 年将以 3.5% 的复合年增长率增长至 2,149 亿美元。随着全球心血管疾病负担持续增加，对有效且可近的治疗方案的需求正以前所未有的速度成长。世界各地的医疗保健系统面临巨大的压力，需要控制冠状动脉疾病、心臟衰竭、心律不整和高血压等疾病，这些疾病仍然是所有地区死亡的主要原因。人们对心血管健康的认识不断提高、诊断率不断上升以及预防保健措施的激增，对市场成长做出了重大贡献。此外，与缺乏运动、不良饮食习惯、压力、吸烟和饮酒等生活方式相关的风险因素也增加了持续药物介入的必要性。

全球人口老化，特别是已开发国家人口老化，进一步加剧了对心血管药物的需求，因为老年人更容易罹患慢性心臟疾病。在创新方面，药物传递技术的进步和下一代治疗方式的引入正在提高治疗效果和患者依从性。主要参与者正在大力投资研发，以推出能够提供更好疗效、更少副作用、并能满足各种患者需求的客製化治疗药物。个人化医疗的日益增长的倾向也正在重塑心血管治疗格局，使公司能够透过更有针对性的治疗方法来满足以前未满足的医疗需求。

市场根据药物类别进行细分，例如抗高血压药、抗高血脂药、抗凝血药、抗心律不整药和其他疗法。其中，光是抗高血压药物领域在 2023 年就创造了 439 亿美元的收入，这得益于全球高血压盛行率的不断上升。此类药物包括 ACE 抑制剂、血管紧张素 II 受体阻断剂 (ARB)、β 受体阻断剂、钙通道阻断剂和利尿剂 - 均被认为对于降低血压和最大限度地降低严重心血管併发症的风险至关重要。 2024 年，高血压细分市场将占据 35.2% 的份额，这主要得益于全球高血压发病率的不断上升及其与中风、肾衰竭和心臟病等危及生命的疾病的直接联繫。有效控制高血压仍然是医疗保健提供者的首要任务，单一疗法和固定剂量联合疗法的可用性确保了治疗可以根据个人需求进行客製化。

2024 年，北美占据全球心血管药物市场的 41.2%，预计到 2034 年将以 3.2% 的复合年增长率成长。该地区受益于强大的医疗保健基础设施、高人均医疗支出以及领先製药公司的存在。此外，美国心血管疾病发生率的上升和人口老化的快速发展也推动了对先进疗法的需求。政府推动的促进医疗创新和治疗可近性的措施预计将进一步支持区域市场扩张。

全球心血管药物市场的主要参与者包括辉瑞、强生、百时美施贵宝、吉利德科学、拜耳、默克、安进、赛诺菲、诺华、阿斯特捷利康、鲁宾和 Viatris。这些公司正在积极扩大其产品组合，推出新型药物和下一代疗法，同时策略合作和研发投资继续推动竞争优势。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 心血管疾病盛行率不断上升
    • 药物配方技术进步
    • 预防保健意识不断增强
  • 产业陷阱与挑战
    • 严格的监管框架
    • 药物研发成本高昂
• 成长潜力分析
• 监管格局
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按药物类别，2021 - 2034 年

• 主要趋势
• 抗高血压药
• 抗高血脂
• 抗凝血剂
• 抗心律不整药物
• 其他药物类别

第六章：市场估计与预测：按适应症，2021 - 2034 年

• 主要趋势
• 高血压
• 高血脂症
• 冠状动脉疾病
• 心律不整
• 其他适应症

第七章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 肠外
• 其他给药途径

第八章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 医院药房
• 网路药局
• 零售药局
• 其他分销管道

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Amgen
• AstraZeneca
• Baxter
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Gilead Sciences
• Johnson & Johnson
• Lupin
• Merck
• Novartis
• Pfizer
• Sanofi
• Viatris

The Global Cardiovascular Drugs Market was valued at USD 153.7 billion in 2024 and is projected to grow at a CAGR of 3.5% to reach USD 214.9 billion by 2034. As the global burden of cardiovascular diseases continues to rise, the demand for effective and accessible treatment options is growing at an unprecedented pace. Healthcare systems around the world are under immense pressure to manage conditions such as coronary artery disease, heart failure, arrhythmias, and hypertension, which remain the leading causes of mortality across all regions. Increasing awareness of cardiovascular health, growing diagnosis rates, and a surge in preventive care initiatives are contributing significantly to market growth. In addition, lifestyle-related risk factors like physical inactivity, poor dietary habits, stress, smoking, and alcohol consumption are amplifying the need for ongoing pharmaceutical intervention.

The aging global population, particularly in developed nations, is further fueling the need for cardiovascular drugs as elderly individuals are more prone to developing chronic heart-related ailments. On the innovation front, advancements in drug delivery technologies and the introduction of next-generation treatment modalities are enhancing both therapeutic efficacy and patient compliance. Key players are investing heavily in research and development to launch drugs that offer better outcomes, reduced side effects, and tailored treatments suited for a variety of patient needs. The growing inclination toward personalized medicine is also reshaping the cardiovascular treatment landscape, allowing companies to address previously unmet medical needs through more targeted therapies.

The market is segmented based on drug classes such as antihypertensives, antihyperlipidemic agents, anticoagulants, antiarrhythmics, and other therapies. Among these, the antihypertensives segment alone generated USD 43.9 billion in 2023, fueled by the increasing prevalence of high blood pressure worldwide. This drug class includes ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, calcium channel blockers, and diuretics-all considered essential in lowering blood pressure and minimizing the risk of severe cardiovascular complications. The hypertension segment accounted for a 35.2% share in 2024, driven by the growing global incidence of high blood pressure and its direct link to life-threatening conditions such as strokes, kidney failure, and heart attacks. Managing hypertension effectively remains a top priority for healthcare providers, and the availability of both monotherapies and fixed-dose combination therapies ensures treatment can be customized to individual needs.

North America held a 41.2% share of the global cardiovascular drugs market in 2024 and is projected to grow at a 3.2% CAGR through 2034. The region benefits from strong healthcare infrastructure, high per capita health expenditure, and the presence of leading pharmaceutical firms. Additionally, the rising incidence of cardiovascular conditions and a rapidly aging population in the U.S. are boosting demand for advanced therapies. Government-driven initiatives promoting healthcare innovation and treatment accessibility are expected to further support regional market expansion.

Key players operating in the Global Cardiovascular Drugs Market include Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Gilead Sciences, Bayer, Merck, Amgen, Sanofi, Novartis, AstraZeneca, Lupin, and Viatris. These companies are actively expanding their portfolios with novel drug classes and next-gen therapies, while strategic collaborations and investments in R&D continue to drive competitive advantage.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements in drug formulation
    • 3.2.1.3 Growing awareness of preventive healthcare
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory frameworks
    • 3.2.2.2 High costs of drug development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Antihypertensives
• 5.3 Antihyperlipidemic
• 5.4 Anticoagulants
• 5.5 Antiarrhythmics
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hypertension
• 6.3 Hyperlipidemia
• 6.4 Coronary artery disease
• 6.5 Arrhythmia
• 6.6 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Online pharmacies
• 8.4 Retail pharmacies
• 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Amgen
• 10.2 AstraZeneca
• 10.3 Baxter
• 10.4 Bayer
• 10.5 Boehringer Ingelheim
• 10.6 Bristol-Myers Squibb
• 10.7 Gilead Sciences
• 10.8 Johnson & Johnson
• 10.9 Lupin
• 10.10 Merck
• 10.11 Novartis
• 10.12 Pfizer
• 10.13 Sanofi
• 10.14 Viatris